【评论】一项对比局部进展期结肠癌术前化疗mFOLFOX6与FOLFOXIRI的Ⅱ期随机研究：JCOG2006

被引：0
|
作者：
窦若虚
机构：
[1] 中山大学附属第五医院胃肠外科
来源：
结直肠肛门外科 | 2023年 / 29卷 / 06期
关键词：
D O I：
10.19668/j.cnki.issn1674-0491.2023.06.013
中图分类号：
R735.35 [];
学科分类号：
摘要：
局部进展期结肠癌（locally advanced colon cancer,LACC）患者进行手术切除后仅辅助化疗的预后较差。伴有危险因素的LACC患者，比如c T4bN+或c T3～4aN2～3期患者的术前化疗备受关注。在这里，作者阐述了JCOG2006的实施依据和研究设计，即这是一项比较术前化疗m FOLFOX6和FOLFOXIRI治疗LACC的Ⅱ期随机研究。研究者评估这些治疗方案的疗效和安全性，并将在随后的Ⅲ期试验中确定哪种治疗方案的应用前景更好。该研究将在2年内从44家机构招募86例患者，主要研究终点是肿瘤退缩评分为0～2分的患者比例，次要研究终点包括总生存期、应答率和不良事件。
引用
收藏
页码：607 / 608
页数：2
相关论文
共 5 条
  • [1] Preoperative Treatment of Locally Advanced Rectal Cancer
    Schrag, Deborah
    Shi, Qian
    Weiser, Martin R.
    Gollub, Marc J.
    Saltz, Leonard B.
    Musher, Benjamin L.
    Goldberg, Joel
    Al Baghdadi, Tareq
    Goodman, Karyn A.
    McWilliams, Robert R.
    Farma, Jeffrey M.
    George, Thomas J.
    Kennecke, Hagen F.
    Shergill, Ardaman
    Montemurro, Michael
    Nelson, Garth D.
    Colgrove, Brian
    Gordon, Vallerie
    Venook, Alan P.
    O'Reilly, Eileen M.
    Meyerhardt, Jeffrey A.
    Dueck, Amylou C.
    Basch, Ethan
    Chang, George J.
    Mamon, Harvey J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (04): : 322 - 334
  • [2] Is There a Role for Neoadjuvant Systemic Therapy for cT4bM0 Colon Cancer? A Propensity-Score Matched Analysis of the National Cancer Database.[J].Kamel Mohamed K.;Shchatsko Anastasiya;Keane Charles A.;Serpa Eduardo;Al Qudah Ghaith;Rahouma Mohamed;Nituica Cristina;Blebea John;Marar Omar.Diseases of the Colon & Rectum.2023,
  • [3] Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
    Morton, Dion
    Seymour, Matthew
    Magill, Laura
    Handley, Kelly
    Glasbey, James
    Glimelius, Bengt
    Palmer, Andy
    Seligmann, Jenny
    Laurberg, Soren
    Murakami, Keigo
    West, Nick
    Quirke, Philip
    Gray, Richard
    FOxTROT Collaborative Grp
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1541 - +
  • [4] Colon Cancer; Version 2.2021; NCCN Clinical Practice Guidelines in Oncology..[J].Benson Al B;Venook Alan P;AlHawary Mahmoud M;Arain Mustafa A;Chen YiJen;Ciombor Kristen K;Cohen Stacey;Cooper Harry S;Deming Dustin;Farkas Linda;GarridoLaguna Ignacio;Grem Jean L;Gunn Andrew;Hecht J Randolph;Hoffe Sarah;Hubbard Joleen;Hunt Steven;Johung Kimberly L;Kirilcuk Natalie;Krishnamurthi Smitha;Messersmith Wells A;Meyerhardt Jeffrey;Miller Eric D;Mulcahy Mary F;Nurkin Steven;Overman Michael J;Parikh Aparna;Pa
  • [5] Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial
    Karoui, Mehdi
    Gallois, Claire
    Piessen, Guillaume
    Legoux, Jean-Louis
    Barbier, Emilie
    De Chaisemartin, Cecile
    Lecaille, Cedric
    Bouche, Olivier
    Ammarguellat, Hanifa
    Brunetti, Francesco
    Prudhomme, Michel
    Regimbeau, Jean-Marc
    Glehen, Olivier
    Lievre, Astrid
    Portier, Guillaume
    Hartwig, Johannes
    Goujon, Gael
    Romain, Benoit
    Lepage, Come
    Taieb, Julien
    [J]. COLORECTAL DISEASE, 2021, 23 (06) : 1357 - 1369
1